Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | USP5 | P45974 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215104 | 0.72 | SMN1; SMN2 (0.43) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL5799649 | 0.69 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL10062641 | 0.67 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL15953657 | 0.65 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL722543 | 0.63 | MGLL (0.48) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL29378993 | 0.63 | MGLL (0.48) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12145717 | 0.61 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL18770671 | 0.61 | KDM4E (0.40) | KDM4EALDH1A1SMN1; SMN2HSD17B10TSHR | |
| SCHEMBL18130849 | 0.61 | MPO (0.40) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL537962 | 0.60 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2KMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9700551-B2 | Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-07-11 | — | — | US | disclosed |
| US-9700551-B2 | Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-07-11 | — | — | US | disclosed |
| US-9700551-B2 | Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-07-11 | — | — | US | disclosed |
| US-20170174657-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. A.F. S.P.A. (IT) | 2017-06-22 | — | — | US | disclosed |
| US-20170174657-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. A.F. S.P.A. (IT) | 2017-06-22 | — | — | US | disclosed |
| US-20170157121-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-06-08 | — | — | US | disclosed |
| US-20170157121-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-06-08 | — | — | US | disclosed |
| US-9611249-B2 | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-04-04 | — | — | US | disclosed |
| US-9611249-B2 | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-04-04 | — | — | US | disclosed |
| US-20160045485-A1 | NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. A.F. S.P.A. (IT) | 2016-02-18 | — | — | US | disclosed |
| US-5034398-A | Analgesics | BEECHAM GROUP P.L.C. (GB) | 1991-07-23 | — | — | US | disclosed |
| US-5017573-A | Serotonin receptor antagonist | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| US-4937247-A | EMETIC AGENTS, ANALGESICS | BEECHAM GROUP P.L.C. (GB) | 1990-06-26 | — | — | US | disclosed |
| US-4853376-A | Benzamides and benzoates having anti-emetic activity | BEECHAM GROUP, P.L.C. (GB) | 1989-08-01 | — | — | US | disclosed |
| US-4853394-A | GASTROINTESTINAL DISORDERS, ANTIEMETICS, ANALGESICS | BEECHAM GROUP P.L.C. (GB) | 1989-08-01 | — | — | US | disclosed |
| US-4798829-A | 1-Azabicyclo[3,2,2]nonane derivatives having 5-HT receptor antagonist activity | BEECHAM GROUP PLC. (GB) | 1989-01-17 | — | — | US | disclosed |
| EP-0230718-A1 | Substituted benzamides and benzoates | BEECHAM GROUP PLC (GB) | 1987-08-05 | — | — | EP | disclosed |
| EP-0223385-A2 | 8-Azabicyclo[3,2,1]octane and 9-azabicyclo[3,3,1]nonane derivatives | BEECHAM GROUP PLC (GB) | 1987-05-27 | — | — | EP | disclosed |
| EP-0214772-A1 | Novel compounds | BEECHAM GROUP PLC (GB) | 1987-03-18 | — | — | EP | disclosed |
| EP-0200444-A2 | Azabicyclononyl-indazole-carboxamide having 5-HT antagonist activity | BEECHAM GROUP PLC (GB) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157121-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | GSK3B, GSK3A, PYGB | KDM4E 2188/4885ALDH1A1 1274/4885SMN1; SMN2 1802/4885 |
| US-20170174657-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | GSK3B, GSK3A, PYGB | KDM4E 2188/4885ALDH1A1 1274/4885SMN1; SMN2 1802/4885 |
| US-20160045485-A1 | NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | GSK3A, GSK3B, PYGB | KDM4E 1990/4885ALDH1A1 1315/4885SMN1; SMN2 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.